Heading Christine E
The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK.
Curr Opin Investig Drugs. 2007 Jan;8(1):71-7.
Cytos Biotechnology AG is developing an intramuscular therapeutic vaccine, CYT-002-NicQb (also known as nicotine-Qbeta), based on its Immunodrug (formerly known as alpha vaccine) nicotine-specific antibody-generating technology, for the potential treatment of nicotine addiction. A phase II trial was initiated in Switzerland in January 2005 and in February 2006, Cytos Biotechnology announced that it planned to begin a phase IIb/III trial in 2007.
赛托斯生物技术股份公司正在基于其免疫药物（原称α疫苗）尼古丁特异性抗体生成技术，开发一种用于潜在治疗尼古丁成瘾的肌肉注射治疗性疫苗CYT - 002 - NicQb（也称为尼古丁 - Qβ）。2005年1月在瑞士启动了一项II期试验，2006年2月，赛托斯生物技术公司宣布计划在2007年开始一项IIb/III期试验。
